Oncosec Medical Incorporated · OTC:ONCSQ
Oncosec Medical — Investor Presentation (November 2022)
27 slides from Oncosec Medical's investor presentation, Nov 22, 2022
Slide 1: OncoSec Overview: Corporate Presentation November 2022
®oncosec IMMUNOTHERAPIES OncoSec Overview Corporate Presentation November 2022
Slide 2: Risk Factors and Forward-Looking Statements
Risk Factors and Forward-Looking Statements This presentation contains forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements provide the Com
Slide 3: OncoSec as a future leader of immuno-oncology therapy
OncoSec as a future leader of immuno-oncology therapy Addressing unmet clinical needs by leveraging innovative intra-tumor drug delivery Vision * We aspire to ignite the immune system to eradicate tumors and restore patients’ lives. Mission * Provide safe and effective solutions for cancer patients
Slide 4: Harnessing the immune system to eradicate cancer
Harnessing the immune system to eradicate cancer Proprietary electroporation (EP) platform designed to elicit tumor-directed immune cell activation against cutaneous and subcutaneous tumors using intratumoral delivery of interleukin 12 (IL-12) plasmid DNA (TAVO™) ImmunoPulse® Platform + Bolsters che
Slide 5: Investment opportunity
Investment opportunity Differentiated Best-in-Class Robust Delivery Platform Therapeutic Potential Development Strategy ImmunoPulse® platform TAVO™-EP differentiates Management team with big designed to overcome key by mechanism of action pharma and biotech experience immuno-therapy and shows effica
Slide 6: ImmunoPulse platform designed to address key clinical unmet needs
ImmunoPulse® platform designed to address key clinical unmet needs * Distinctive intratumoral delivery c 5 by EP applicable to cutaneous and Illustration of electroporation (EP) process subcutaneous solid tumors clinical procedure requires only a few seconds per individual EP event. Clinical efficac
Slide 7: Positioning of OncoSec's TAVO-EP
Positioning of OncoSec’s TAVO™-EP @®oncosec
Slide 8: The market driven by checkpoint modulators is growing rapidly
The 10 market driven by checkpoint modulators is growing rapidly Global Market Analysis and Forecast of Immuno-Oncology Approaches 8 160 $143 B 140 ge CAGR 23% ‘g 100 38 S 80 79 g 71 5 © | sae a = 40 E E 53 2 = al d : < 0 2021 2022 ©«2023«« 2024» 2025-2026 «=— 2027 Year Cell therapies Bispecific ant
Slide 9: External market research projects rapid growth of the intratumoral market
External market research projects rapid growth of the intratumoral market Market Synopsis 2021 Market: USS 111.41 Billion CABELAS 2027 Market: US$ 212.92 Billion Largest North America * Several independent market reports project the pr intratumoral cancer therapy market to grow rapidly | Astrazeneca
Slide 10: TAVO-EP enables delivery of well-validated anti-tumor agent IL-12
TAVO™-EP enables delivery of well-validated anti-tumor agent IL-12 * IL-12 is an important pro-inflammatory cytokine J that stimulates a broad set of immune effector cells to generate a strong anti-tumor response * Killing of cancer cells exposes antigen presenting : cells to tumor antigens and resu
Slide 11: Future expansion opportunities for ONCS growth into a leading IO company
Future expansion opportunities for ONCS growth into a leading |O company key immune regulators Therapeutic modalities that are applicable for Py ‘ E to other chemical entities to mitigate risks, broad h intratumoral électroporation (ITEP) xpansion to other chemi ities to mitigate risks, broaden reac
Slide 12: Clinical Programs
Clinical Programs @®oncosec
Slide 13: Sharpened focus on melanoma and upside potential in other tumor types
Sharpened focus on melanoma and upside potential in other tumor types ee 3 TAVO™ + 4 ; ; — =e = Penibrolicumab: KEYNOTE-695' Advanced Melanoma & MERCK BICR data readout in 1023 2 H TAvO Neoadjuvant Operable Locally / s ™ 4 e . leoadjuvant Operable Local Mol T Fa 2 Nivolumab OMS-104 (IST Regionally A
Slide 14: TAVO-EP is targeting the large, growing melanoma market
TAVO™-EP is targeting the large, growing melanoma market Major Markets? Incidence Global Market Size (2021 - 2028) Ci02%) 290K $208 side 200K $158 150K S108 $8.18 : ey 038 $0.68 100k 200 k mm 206 K I 2212 era su76 aa... gsas | °° 50K $08 0.68 ae Other 7024 wRelatiimas = 75 win-raa 2020 2022 ©«-2024
Slide 15: Great unmet need remains in melanoma
Great unmet need remains in melanoma Primary Resistance Secondary Resistance Among initial PD-1 responders, ~40% acquire resistance and progress within 5 years? Most patients receive PD-1 mono- or combo-therapy in the 1L, yet 40 - 65% fail to respond? Key Unmet Needs Low ORR After PD-1 Therapy Only
Slide 16: Melanoma: Advanced treatment landscape
inoma: Advani Immunotherapy is the preferred treatment option for advanced melanoma BRAF Wild Type (50-60%) BRAF Mutated (40-50%) aL aL 3L+ me Ee Gi ESCO I EI coco Bluestar\ snce:noo aides sues enaais © Immunotherapy is the preferred therapy for MM patients regardless of BRAF status — Physicians pre
Slide 17: TAVO-EP plus pembrolizumab is seen as attractive treatment alternative
TAVO™-EP plus pembrolizumab is seen as attractive treatment alternative Initial Reactions and Noted Advantages of TAVO + Pembro ‘Advantages of TAVO * Generally, stakeholders are pleased with the safety and efficacy profile exhibited by TAVO + pembrolizumab * Oncologists hone in on the particular nee
Slide 18: KEYNOTE-695 trial design
KEYNOTE-695 trial design + TAVO™ + pembrolizumab, Survival Follow-up Patients with advanced melanoma and documented confirmed progression on immediate prior anti-PD-1 antibody therapy Key eligibility criteri: TAVO™-EP Days 1, 5, 8 q6w Pembrolizumab 200 mg IV q3w Primary: ORR (BICR) Endpoints: Second
Slide 19: KEYNOTE-695 Cohort 1a: RECIST v1.1 response
KEYNOTE-695 Cohort 1a: RECIST v1.1 response Efficacy Evaluable (N=101) n Objective Response Rate (CR + PR) 19 (18.8) 95% Exact Binomial Confidence Interval 11.7, 27.8 Complete Response (CR) 3(3.0) Partial Response (PR) 16 (15.8) Stable Disease (SD) 22 (21.8) Progressive Disease (PD) 60 (59.4) Durabl
Slide 20: KEYNOTE-695 Cohort 1a: best change in measurable tumor lesions
KEYNOTE-695 Cohort 1a: best change in measurable tumor lesions Best % Change from Baseline in Total Tumor Burden ° Efficacy evaluable subject with post-baseline target lesion assessment n=99 60 -|™ Complete Response m@ Partial Response 9 -|@ Stable Disease @ Progressive Disease @Not Evaluable -100 4
Slide 21: KEYNOTE-695 Cohort 1a: duration of response
KEYNOTE-695 Cohort 1a: duration of response RECIST v1.1 Responders, N = 19 10 {= Overall (N=19) Status 1 (%) . Event 6 (31.6) . 20 Censored 13 (68.4) S 3 Cy Duration of Response months (95% Cl) 3 ‘Q1 (95% Cl) 8.3 (5.0, NE) F Median (95% Cl) NE (8.1, NE) i 03 (95% Cl) NE (23.3, NE) =» Responding Rate
Slide 22: KEYNOTE-695 Cohort 1a: overall survival (OS)
KEYNOTE-695 Cohort 1a: overall survival (OS) Overall Survival N=105 wf On 05 Median months (95% Cl) 22.7 (14.4, 35.5) wo ’ Status, n (96) z Death 61 (58.1) | oa Censored 44 (41.9) g $ i bi OS rate (95% Cl) ¢ ° tH at 6 months 91.4 (84.1, 95.4) i a 2 kn rot at 12 months 69.0 (59.1, 77.0) es ro at 18 m
Slide 23: KEYNOTE-695 Cohort 1a: comparison to benchmarks in post PD-1 setting
KEYNOTE-695 Cohort 1a: TAVO™-EP + pembrolizumab comparison to benchmarks in post PD-1 setting * TAVO™-EP + pembrolizumab ORR}, in patients with confirmed progression on anti-PD1 therapy, was 18.8% based on investigator-assessment - Ipilimumab BICR-assessed ORR, in ipilimumab naive patients with conf
Slide 24: TAVO-EP is a well tolerated safety profile for late-stage melanoma
TAVO™-EP is a well tolerated safety profile for late-stage melanoma Company MOA Dev. Stage Safety/AEs : Tavon+ \®oncosec reanicee 2 activator Phase 2b 5.4% Grade’ AEs, no Grade 4/5 TEAES TOVANCE LifleuceyiN-a4a jr Phase2 _| 82% Grade 3+ thrombocytopenia, 56% Grade 3+ anemia, 55% Grade 3+ febrile neu
Slide 25: KEYNOTE-695 Cohort 1a: conclusions
KEYNOTE-695 Cohort 1a: conclusions * The observed ORR? of 18.8% with TAVO™-EP + pembrolizumab, in patients refractory to anti-PD-1 therapy, demonstrates that intratumoral IL-12 provides a critical immune regulatory signal that has the potential to reverse tumor resistance to prior anti-PD-1 therapy.
Slide 26: Experienced industry leaders with track record of success
Experienced industry leaders with track record of success Leadership Team Board of Directors Robert H. Arch, Ph.D President and Chief Executive Officer Sandra Aung, Ph.D Senior Vice President, Clinical Development Bridget O'Keeffe, Ph.D Vice President, Clinical Development S88 David Canton, Ph.D Vic
Slide 27: Thank you!
®oncosec IMMUNOTHERAPIES Thank you!
OncoSec Medical — Investor Presentation (November 2022) on 6ix